Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
second-generation peripheral HDAC6 inhibitor (Augustine Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Augustine Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Augustine Therapeutics is developing a second-generation, peripherally-restricted small molecule inhibitor of Histone Deacetylase 6 (HDAC6) specifically for the treatment of cardiometabolic diseases. This program utilizes a novel non-hydroxamate and non-hydrazide chemotype designed to selectively inhibit the catalytic activity of the cytosolic enzyme HDAC6 while preserving its beneficial non-catalytic functions. This approach aims to avoid the toxicity and poor drug-like properties associated with earlier generations of HDAC6 inhibitors. By targeting HDAC6 in peripheral tissues, the drug candidate is intended to modulate cellular processes such as microtubule stability and transport without crossing the blood-brain barrier. The program is currently in the advanced lead optimization phase of preclinical development.
- Other names
- second-generation peripherally-restricted HDAC6 inhibitorAugustine Therapeutics second-generation HDAC6 inhibitor
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on second-generation peripheral HDAC6 inhibitor (Augustine Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on second-generation peripheral HDAC6 inhibitor (Augustine Therapeutics).